Drug & intervention
tetrabenazine
RxCUI 10390
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Background context
Tetrabenazine
Tetrabenazine is a drug for the symptomatic treatment of hyperkinetic movement disorders. It is sold under the brand names Nitoman and Xenazine among others. On August 15, 2008, the US Food and Drug Administration (FDA) approved the use of tetrabenazine to treat chorea associated with Huntington's disease. Although other drugs had been used "off-label", tetrabenazine was the first approved treatment for Huntington's disease in the United States. The compound has been known since the 1950s.
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.Conditions being studied
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.